Liraglutide

WHAT IT DOES

Liraglutide is an acylated analogue of human GLP-1 with 97% amino acid homology to the native hormone, engineered for a protracted 24-hour exposure profile through slowed release from the injection site, metabolic stabilization, and reduced renal filtration (Jacobsen 2016, PMID: 26597252). It acts on GLP-1 receptors to increase glucose-dependent insulin secretion, suppress glucagon, reduce appetite and energy intake, and slow gastric emptying.

Two mechanistic details matter for anyone building a supplement routine around it.

First, the appetite effect and the gastric emptying effect are not the same mechanism and do not follow the same time course. In a rat study comparing liraglutide against exenatide, the acute reduction in gastric emptying was markedly diminished after 14 days of liraglutide dosing while the body weight effect persisted, suggesting the gastric-inhibitory receptors desensitize under continuous 24-hour exposure while the central appetite signaling does not (Jelsing 2012, PMID: 22226053). This is preclinical and should not be read as a promise that your nausea resolves on a schedule, but it is consistent with the clinical pattern of gastrointestinal symptoms that diminish over time.

Second, the insulin effect is glucose dependent. Because liraglutide increases insulin secretion only in proportion to prevailing glucose, hypoglycemia risk from the drug alone is low, and the counter-regulatory hormone response to hypoglycemia is largely unaltered (Jacobsen 2016, PMID: 26597252). Hypoglycemia risk in practice comes almost entirely from what is stacked on top: sulfonylureas, insulin, and glucose-lowering supplements.

SAFETY PROFILE

Liraglutide is a peptide and is not a meaningful inhibitor or inducer of the classic cytochrome P450 pathways, so the pharmacokinetic interaction profile is unusually clean. A clinical pharmacology review found no clinically relevant changes in overall concentrations of paracetamol, atorvastatin, griseofulvin, digoxin, lisinopril, or oral combination contraceptives when co-administered with liraglutide (Jacobsen 2016, PMID: 26597252), a conclusion echoed in clinical practice guidance stating these agents do not require dose adjustment when combined with liraglutide (Peterson 2010, PMID: 20949699). The real risks are pharmacodynamic and mechanical, not metabolic.

Critical Interactions (Do Not Combine Without Medical Supervision)

Moderate Interactions (Monitor Closely)

Theoretical/Low-Risk Interactions